Soluble CD4 and the treatment of AIDS.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Soluble CD4 and the treatment of AIDS.

Symp Nonhum Primate Models AIDS. 1990 Nov 28-30;8:41 (abstract no. 25). Unique Identifier : AIDSLINE PRIM8/900025
Letvin NL; Watanabe M; Harvard Medical School, New England Regional Primate Research; Center, One Pine Hill Drive, Southborough, MA 01772

Abstract: Since the CD4 molecule is a high affinity cell surface receptor for the human immunodeficiency virus (HIV), it has been suggested that a soluble truncated form of CD4 may compete with cell surface CD4 for HIV binding and thus be of use in the therapy of AIDS. We have utilized the simian immunodeficiency virus of macaques (SIV mac)/ rhesus monkey model to explore another possible therapeutic application of CD4 in AIDS, the use of recombinant soluble CD4 (rsCD4) as an immunogen. SIVmac-infected rhesus monkeys immunized with human rsCD4 developed not only an anti-human CD4 but also an anti-rhesus monkey CD4 antibody response. Coincident with the generation of this antibody response, SIVmac could not be isolated from peripheral blood lymphocytes (PBLs) and bone marrow macrophage of these animals. Furthermore, the decreased number of both granulocyte/macrophage and erythrocyte colonies grown from the bone marrow of these immunized monkeys rose to normal levels. These findings suggest that a modified human CD4 molecule serving as an immunogen might elicit an antibody response in man which could induce a beneficial therapeutic response in HIV-infected individuals.

Keywords: Animal Antibodies, Viral/BIOSYNTHESIS Antigens, CD4/*IMMUNOLOGY Blood Cell Count Bone Marrow/CYTOLOGY Cells, Cultured Disease Models, Animal Erythrocytes/IMMUNOLOGY Granulocytes/IMMUNOLOGY Macaca mulatta Macrophages/IMMUNOLOGY Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Solubility SIV/*IMMUNOLOGY Vaccines, Synthetic Viral Vaccines ABSTRACT
910730
M9170969

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .